Delving into the Latest Updates on FT-002 with Synapse

Overview

Basic Info

Drug Type

AAV based gene therapy

Synonyms

Target

RPGR

Action-

Mechanism

RPGR gene transference

Therapeutic Areas

Congenital DisordersEye DiseasesOther Diseases

Active Indication

X-linked retinitis pigmentosa

Inactive Indication-

Originator Organization

Frontera Therapeutics, Inc.

Active Organization

Frontera Therapeutics, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

RegulationFast Track (United States), Orphan Drug (United States)

Login to view timeline

The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis Pigmentosa GTPase Regulator) gene mutation-associated X-linked retinitis pigmentosa, of XLRP. This study includes Phase I (dose escalation phase) and Phase II (dose expansion phase).

Start Date01 Apr 2024

Sponsor / Collaborator

Frontera Therapeutics, Inc.

NCT05874310

/ RecruitingEarly Phase 1

An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

Start Date01 Feb 2023

Sponsor / Collaborator

Frontera Therapeutics, Inc.

[+3]

100 Clinical Results associated with FT-002

Login to view more data

100 Translational Medicine associated with FT-002

Login to view more data

100 Patents (Medical) associated with FT-002

Login to view more data

2

Literatures (Medical) associated with FT-002

01 Mar 2020·Probiotics and Antimicrobial ProteinsQ2 · ENGINEERING & TECHNOLOGY

Combined and Singular Effects of Dietary PrimaLac® and Potassium Diformate (KDF) on Growth Performance and Some Physiological Parameters of Rainbow Trout (Oncorhynchus mykiss)

Q2 · ENGINEERING & TECHNOLOGY

Article

Author: Hoseinifar, Seyed Hossein ; Bahrami Gorji, Sara ; Naderi Farsani, Mehdi ; Rashidian, Ghasem ; Van Doan, Hien

The present study was conducted to assess the effects of combined and singular dietary administration of PrimaLac® and potassium diformate (KDF) on growth performance, feed utilization, digestive enzymes activity, and some physiological parameters of rainbow trout (Oncorhynchus mykiss) juvenile. Three hundred sixty rainbow trout juveniles (25 ± 1.8 g) were randomly stocked in 300-L tanks (30 fish/tank), and fed three times daily on a basal diet (control), diets incorporated with 12 g kg^-1 KDF (FT₁), 1.5 g kg^-1 PrimaLac® (FT₂), and combination of 1.5 g kg^-1 probiotic and 12 g kg^-1 KDF (FT₃) in triplicates, for 8 weeks. At the end of feeding trial, growth performance, body composition, digestive enzymes, liver enzymes, and biochemical parameters were measured. Our results revealed that combined administration of PrimaLac® and KDF (FT₃) exhibited significantly higher weight gain and specific growth rate (SGR) compared to other groups (P < 0.05). Glucose and cortisol levels showed no significant differences between fish fed different test diets (P > 0.05). The highest lipase, protease and amylase activity were observed in group of fish fed FT₃ followed by FT₂ and FT₁. Besides, the diets FT₂ and FT₃ led to significantly lower of ALP, ALT, and AST compared to control group. The present results indicated that combined administration of PrimaLac® and KDF can be considered as a beneficial feed additive and growth promotor for O. mykiss juvenile.

01 Jan 1994·Immunology

Isolation, sequence and expression of a cDNA encoding the alpha-chain of the feline CD8.

Article

Author: Mikami, T ; Miyazawa, T ; Maeda, K ; Kawaguchi, Y ; Pecoraro, M R ; Tohya, Y ; Toyosaki, T ; Norimine, J ; Kai, C

We have cloned, sequenced and expressed a cDNA encoding the alpha-chain of feline CD8. This clone, named FT8-10, has an open reading frame with 720 nucleotides in length encoding a protein with 239 amino acid residues. Sequence analysis has revealed that the feline CD8 alpha-chain (CD8 alpha) shares significant homology with human (T8/Leu-2), bovine (BoCD8), rat (MRC OX8) and mouse (Lyt-2) CD8 alpha subunits. Cysteine residues as well as the tyrosine kinase p56lck binding site are well conserved. Besides, no putative N-linked glycosylation site was found. Interestingly, immunofluorescence analysis of COS-7 cells transfected with feline CD8 alpha expression plasmid driven by SR alpha promoter showed that the expressed feline CD8 alpha cross-reacted with an anti-human CD8 alpha monoclonal antibody OKT8, but did not react with an anti-feline monoclonal antibody, FT-2, which is thought to recognize the feline analogue of the human T8/Leu-2 and murine Lyt-2 molecules expressed on cytotoxic/suppressor T cells.

100 Deals associated with FT-002

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
X-linked retinitis pigmentosa	Phase 2	China	Frontera Therapeutics, Inc.	01 Apr 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05874310 (FT-002, ASGCT2025)	Early Phase 1	X-linked retinitis pigmentosa RPGR gene mutation	18	FT-002 5×10^10 vg/eye	qxluqkncjp(jdhipmqlde) = signs of FT-002 related ocular inflammation observed in 8/18 (44%) participants but were controllable via topical use of steroids skdufmxaja (jdswqmffeh ) View more	Positive	13 May 2025